Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Alkido Pharma Inc.Incorporated and changed its name toDominari Holding Inc. in December 2022.
Latest shares articles
Forex CFDs: Understanding currency forwards vs spot markets
Spot or forward? These two forex markets behave differently, and now you can trade both with us as forex CFDs. Here’s how they work, and what sets them apart.
14:48, 31 July 2025
Crypto CFDs: Popular cryptocurrencies for trading
Discover which cryptocurrencies are trending for CFD trading in 2025 – from bitcoin to newly listed coins like SUI and PEPE.
10:46, 31 July 2025
Trading the Nasdaq 100 Amidst Big Tech Earnings
Microsoft and Meta notably impressed powering the tech-heavy index higher in the futures market, but it’s two down and two more to go as both Apple and Amazon are next.
07:04, 31 July 2025
Ripple price prediction: Third-party price target
Ripple, launched in 2012 with the XRP Ledger, aims to make cross-border payments faster and cheaper using its native token, XRP. Backed by financial institutions and a strong market presence, it remains a major crypto asset by market cap.
14:34, 30 July 2025
Ratings and Reviews
Ratings and Reviews
